My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Calidi Biotherapeutics, Inc. Common Stock (NY:CLDI)

1.570 +0.120 (+8.28%)
Official Closing Price Updated: 8:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Calidi Biotherapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 Next >
Researchers Find That Common Nutrient Could Supercharge the Immune Cells Fighting Cancer
Via Investor Brand Network
How Patients Can Boost Dietary Nutrient Intake During Cancer Treatment
Via Investor Brand Network
Study Finds That Common Sweetener Could Compromise Cancer Treatment Effectiveness
Via Investor Brand Network
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
New Study Discovers Unexpected Reason for Resistance to Cancer Immunotherapy
Via Investor Brand Network
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option
Via Investor Brand Network
Scientists Turn Bacteria into Trojan Horses to Deliver Anti-Cancer Viruses into Tumors
Via Investor Brand Network
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $6 Million Public Offering
Via Investor Brand Network
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Q2 2025 Results and Business Highlights
Via Investor Brand Network
Breakthrough Treatment for Lung Cancer Uses Mitochondria to Supercharge Immune Cells
Via Investor Brand Network
New Genetic Discovery Could Boost Cancer Immunotherapy
Via Investor Brand Network
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Specificity Inc. (OTCID: SPTY) AI-Powered Technology Poised to Disrupt the Media Sector – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence Fraud Regulatory Compliance
Study Discovers That Autoantibodies in Patients Could Boost Cancer Immunotherapy
Via Investor Brand Network
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Fast Track Designation for CLD-201 in Soft Tissue Sarcoma
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces 1-for-12 Reverse Stock Split Effective August 5
Via Investor Brand Network
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar Highlighting RedTail Platform and Oncology Advancements
Via Investor Brand Network
Study Provides Valuable Insights About Non-Smokers Who Develop Lung Cancer
Via Investor Brand Network
Study Suggests Herpes Virus Can Be Modified to Fight Advanced Melanoma
Via Investor Brand Network
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in NetworkNewsWire Spotlight on Genetic Medicines
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Raises $4.6 Million Through Warrant Exercise Agreement
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
From Calidi Biotherapeutics Inc.
Via GlobeNewswire
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via Investor Brand Network
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform
Via Investor Brand Network
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
From Calidi Biotherapeutics Inc.
Via GlobeNewswire
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Via Investor Brand Network
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Study Discovers Genetic Mutation that Makes Solid Tumors Unresponsive to Immunotherapy
Via Investor Brand Network
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.